The latest biotech news

News and Trends 11 Apr 2023

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment

InflaRx N.V., a German company developing anti-inflammatory therapeutics by targeting the complement system, has announced that Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults. Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody that acts on […]

April 5, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition

Ginkgo Bioworks has acquired StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets. A secondary close is scheduled upon the transfer of certain additional in-license agreements to Ginkgo Bioworks. Ginkgo Bioworks will incorporate the assets and IP into its end-to-end AAV gene therapy development platform, allowing the company’s customers to leverage new tools to […]

April 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

Cure Ventures launches with $350M to support life sciences companies

Cure Ventures, a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, has closed its inaugural fund, Cure Ventures Fund I, L.P., at its targeted hard-cap of $350 million in capital commitments. The fund is supported by a syndicate of U.S. and internationally-based investors that includes state and city public pension […]

April 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

Mosaic Therapeutics closes $28M series A funding

Mosaic Therapeutics, Ltd has closed its $28 million series A funding round. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital. The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic Therapeutics’ pipeline […]

April 5, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

Alzamend pushing ahead with Alzheimer’s vaccine trial

Alzamend Neuro, Inc. has announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type. The purpose of the trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of Alzamend Neuro’s ALZN002 compared with that of placebo in […]

April 4, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

iNtRON looks to control colorectal cancer through microbiome

iNtRON Biotechnology has announced that it has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model. P18-BE3CRC is a drug candidate from iNtRON Biotechnology’s PHAGERIA platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) for cancer control. Bacteriophages have been used for R&D on bacterial infectious diseases, but recently […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

New research may lead to gene therapies for kidney disease

Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially lethal genetic disease—about a half million people in the U.S. alone suffer from the condition. There is currently no cure, but new research could open the door to new gene therapies for treating most cases of this kidney disease. For several decades, researchers have […]

April 4, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

Discovery could lead to cancer drugs with fewer side effects

Many anticancer drugs have serious side-effects in clinical practice. Kinesin inhibitors block kinesin motor proteins required for cancer cell division, and are promising anticancer drug candidates with minimal side-effects. However, their association with kinesin proteins remains unclear. Researchers from Japan have addressed this by solving the crystal structure of the complex formed by the kinesin […]

April 4, 2023 - 4 minutesmins - By Jim Cornall

digital medicine artificial intelligence AI

News and Trends 31 Mar 2023

Sofinnova Partners dives into digital medicine, funds new companies

Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has launched a new investment strategy focused on digital medicine. The strategy, which has already seen Sofinnova Partners investing in biotech companies, will be headed by partners Edward Kliphuis and Simon Turner. Sofinnova Digital Medicine will back entrepreneurs innovating at […]

March 31, 2023 - 5 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment

Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition

Cure Ventures launches with $350M to support life sciences companies

Mosaic Therapeutics closes $28M series A funding

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

Alzamend pushing ahead with Alzheimer’s vaccine trial

iNtRON looks to control colorectal cancer through microbiome

New research may lead to gene therapies for kidney disease

Discovery could lead to cancer drugs with fewer side effects

Sofinnova Partners dives into digital medicine, funds new companies

Subscribe to our newsletter to get the latest biotech news!